Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Cetirizine
Therapeutic Area : Undisclosed
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase 2 Study IV QUZYTTIRâ„¢ (Cetirizine Hydrochloride Injection) vs V Diphenhydramine
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 06, 2019
Lead Product(s) : Cetirizine
Therapeutic Area : Undisclosed
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cetirizine
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Genentech
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 25, 2019
Lead Product(s) : Cetirizine
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Genentech
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cetirizine
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Cetirizine Chewable Bioequivalence and Food Effect Study
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 11, 2018
Lead Product(s) : Cetirizine
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cetirizine
Therapeutic Area : Immunology
Study Phase : Phase IV
Sponsor : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 13, 2016
Lead Product(s) : Cetirizine
Therapeutic Area : Immunology
Highest Development Status : Phase IV
Sponsor : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cetirizine
Therapeutic Area : Undisclosed
Study Phase : Phase III
Sponsor : Ora, Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 29, 2016
Lead Product(s) : Cetirizine
Therapeutic Area : Undisclosed
Highest Development Status : Phase III
Sponsor : Ora, Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cetirizine
Therapeutic Area : Immunology
Study Phase : Phase IV
Sponsor : Biogenics Research Chamber, LLC
Deal Size : Inapplicable
Deal Type : Inapplicable
Comparability and Standardization of Controlled Allergen Challenge Facilities
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 07, 2015
Lead Product(s) : Cetirizine
Therapeutic Area : Immunology
Highest Development Status : Phase IV
Sponsor : Biogenics Research Chamber, LLC
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cetirizine
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Multi-Center Study Evaluating the Safety of AC-170 0.24%
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 07, 2014
Lead Product(s) : Cetirizine
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cetirizine
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Multi-Center, Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 19, 2013
Lead Product(s) : Cetirizine
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cetirizine
Therapeutic Area : Immunology
Study Phase : Phase IV
Sponsor : McNeil Consumer Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of Bronchodilation Effects of Cetirizine
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 01, 2013
Lead Product(s) : Cetirizine
Therapeutic Area : Immunology
Highest Development Status : Phase IV
Sponsor : McNeil Consumer Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cetirizine
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Single-Center,Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 14, 2012
Lead Product(s) : Cetirizine
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable